2022 World Conference on Lung Cancer (ePosters)-EP11.01-008. Discrepancy in MET Exon 14 Skipping Mutation Measurement Between ArcherMET and Oncomine Dx Target Test System

EP11.01-008. Discrepancy in MET Exon 14 Skipping Mutation Measurement Between ArcherMET and Oncomine Dx Target Test System

Back to course

Pdf Summary

This research article discusses the discrepancy observed between two next-generation sequencing (NGS) methods, ArcherMET and Oncomine Dx Target Test System (ODxTT), in detecting MET exon 14 skipping mutation (METex14skipping) in non-small cell lung cancer (NSCLC) patients. METex14skipping is an important therapeutic target gene in NSCLC for the administration of selective MET inhibitors. The study aims to explore factors that may cause the discrepancy between the two NGS methods.<br /><br />The researchers analyzed the genetic mutations of NSCLC patients using ODxTT and then confirmed the results using ArcherMET. They found that the discrepancy group had significantly lower read counts compared to the concordant group. Additionally, all cases of discrepancy had an allele frequency of METex14skipping less than 1% and did not have any mutations causing METex14skipping.<br /><br />The study suggests several factors that may contribute to the discrepancy. Mutations and deletions in the primer region may interfere with ODxTT amplicon sequencing PCR. There is also a possibility of false positivity in ODxTT when the number of mutated reads is low. However, some cases were still detected by ODxTT with a small number of read counts. Allele frequency may also play a role in the discrepancy.<br /><br />The conclusion of the study is that the discrepancy between ODxTT and ArcherMET may be related to a low allele frequency of 1% or less. Furthermore, all discrepancy cases did not have any mutations causing METex14skipping.<br /><br />Overall, this research highlights the challenges and discrepancies in measuring METex14skipping mutation using different NGS methods. Understanding the factors contributing to such discrepancies is crucial for accurate detection and treatment decisions in NSCLC patients. Further studies and improvements in NGS methods are warranted to overcome these challenges.

Asset Subtitle

Kanako Shinada

Meta Tag

Speaker Kanako Shinada

Topic Pathology - Genomics & Analytics

Keywords

next-generation sequencing

ArcherMET

Oncomine Dx Target Test System

MET exon 14 skipping mutation

non-small cell lung cancer

NSCLC

therapeutic target gene

MET inhibitors

discrepancy

allele frequency